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A B S T R A C T
Purpose
We investigated whether bortezomib during induction and maintenance improves survival in
newly diagnosed multiple myeloma (MM).
Patients and Methods
In all, 827 eligible patients with newly diagnosed symptomatic MM were randomly assigned to
receive induction therapy with vincristine, doxorubicin, and dexamethasone (VAD) or bortezomib,
doxorubicin, and dexamethasone (PAD) followed by high-dose melphalan and autologous stem-
cell transplantation. Maintenance consisted of thalidomide 50 mg (VAD) once per day or
bortezomib 1.3 mg/m2 (PAD) once every 2 weeks for 2 years. The primary analysis was
progression-free survival (PFS) adjusted for International Staging System (ISS) stage.
Results
Complete response (CR), including near CR, was superior after PAD induction (15% v 31%;
P  .001) and bortezomib maintenance (34% v 49%; P  .001). After a median follow-up of 41
months, PFS was superior in the PAD arm (median of 28 months v 35 months; hazard ratio [HR],
0.75; 95% CI, 0.62 to 0.90; P  .002). In multivariate analysis, overall survival (OS) was better in
the PAD arm (HR, 0.77; 95% CI, 0.60 to 1.00; P  .049). In high-risk patients presenting with
increased creatinine more than 2 mg/dL, bortezomib significantly improved PFS from a median of
13 months to 30 months (HR, 0.45; 95% CI, 0.26 to 0.78; P  .004) and OS from a median of 21
months to 54 months (HR, 0.33; 95% CI, 0.16 to 0.65; P  .001). A benefit was also observed in
patientswith deletion17p13 (medianPFS, 12 v22months;HR, 0.47; 95%CI, 0.26 to 0.86;P .01;median
OS, 24 months v not reached at 54 months; HR, 0.36; 95% CI, 0.18 to 0.74; P  .003).
Conclusion
Bortezomib during induction and maintenance improves CR and achieves superior PFS and OS.
J Clin Oncol 30:2946-2955. © 2012 by American Society of Clinical Oncology
INTRODUCTION
High-dose melphalan (HDM) followed by autolo-
gous stem-cell transplantation(ASCT) is considered
a standardof care for youngerpatientswithmultiple
myeloma (MM).1-3 In the setting of ASCT, high
complete response (CR) rates have consistently re-
sulted in prolonged progression-free survival (PFS)
and overall survival (OS).4 Chemotherapywith vin-
cristine, doxorubicin, and dexamethasone (VAD)
has been a standard induction in this setting.5,6
Proteasome inhibition (bortezomib) and immu-
nomodulatory drugs (thalidomide, lenalido-
mide) have significant activity in patients with
relapsed/refractory MM.7-10 Bortezomib com-
bined with melphalan and prednisone achieves
30% CR in newly diagnosed patients who are not
eligible for transplantation.11 Likewise, bort-
ezomib combined with dexamethasone (VD) and
thalidomide (VTD) results in an improvement of
CR and in prolongation of PFS.12,13 Although CR
predicts for prolonged survival, these scheduleshave
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not resulted in an improved OS.14,15 In high-risk patients with MM
presenting with renal failure or with deletion of chromosome 17p13
and/or t(4;14), survival remains poor.16-18 Consolidation or mainte-
nance therapy following high-dose therapy improves CR rate and
PFS.19 Maintenance with thalidomide prolongs PFS but not OS.20-22
Lenalidomide maintenance improved PFS in one transplantation
study and improvedbothPFS andOS in another.23,24 Bortezomibhas
been studied as post-ASCT consolidation therapy.13,25,26 Use of bort-
ezomibasmaintenance therapyhasnot yet beenaddressed in younger
patients.We report on the results of an open-label randomized phase
III trial that evaluated sustained bortezomib treatment during induc-
tion andmaintenance.
PATIENTS AND METHODS
Eligibility
Patients 18 to 65 years of age with newly diagnosedMMDurie-Salmon
stage II to III, WHO performance status 0 to 2, or WHO 3 when caused by
MM, were eligible. Exclusion criteria were systemic amyloid light chain amy-
loidosis, nonsecretoryMM, neuropathy grade 2, active malignancy during
the past 5 years with the exception of basal carcinoma of the skin or stage 0
cervical carcinoma, HIV positivity, serum bilirubin 30 mol/L or amino-
transferases  2.5  normal level. Prior corticosteroids were allowed for a
maximumof 5 days. Patients with renal impairmentwere not excluded. Local
radiotherapy for painful MM lesions was allowed.
Study Design
This investigator-sponsored, open-label, randomized phase III trial was
designed and performed by the Dutch-Belgian Hemato-Oncology Coopera-
tive Group (HOVON) and the German Multicenter Myeloma Group
(GMMG) by using one protocol, data management, and analysis. Patients
were randomly assigned 1:1 to VAD induction,5 followed by intensification
with HDM and ASCT, followed by maintenance therapy with thalidomide
(arm A) or bortezomib, doxorubicin, and dexamethasone (PAD),27 followed
by intensification withHDMand ASCT, followed bymaintenance with bort-
ezomib for 2 years (arm B). This design was chosen to evaluate sustained
bortezomib treatment (64 administrations) as in VISTA.11 Random assign-
ments to VAD or PADwere balanced with use of a biased-coinminimization
procedure, with the bias dependent on the average imbalance between num-
bers of patients already assigned to each treatment arm overall and within the
stratification factors of the newpatient.28Theminimizationwas initially based
onhospital,Durie-Salmonstage (2v3)and lactatedehydrogenase level (up-
per limit of normal v greater than upper limit of normal). After the third
amendment, the minimization was based on hospital and International
Staging System (ISS) stage (I v II v III). Patients were randomly assigned via a
Web-based application, Trial Online Process, and the assigned treatment arm
was sent immediately via e-mail to local investigators. VADwas administered
as three cycles of intravenous (IV)vincristine0.4mgperdayondays1 through
4, doxorubicin 9mg/m2 per day ondays 1 through 4, andoral dexamethasone
40 mg per day on days 1 through 4, 9 to 12, and 17 to 20, every 28 days. PAD
induction included three cycles of IVbortezomib1.3mg/m2perdayondays 1,
4, 8, and 11; doxorubicin 9 mg/m2 per day on days 1 through 4, and oral
dexamethasone 40mgper day ondays 1 through 4, 9 to 12, and 17 to 20, every
28 days. Stem-cell collection was performed 4 to 6 weeks after induction.20
HDM 200mg/m2 and ASCT were administered as described.20 Per protocol,
one or two cycles of HDMwere planned, according to HOVON (single) and
GMMG(double) standards, respectively. Patients randomly assigned toVAD
receivedmaintenancewith thalidomide 50mgper day for 2 years, starting at 4
weeks after HDM. Patients randomly assigned to PAD received maintenance
with IVbortezomib1.3mg/m2once every 2weeks for 2 years (n52) starting
at 4weeks afterHDM.Patientswith anHLA-identical sibling couldproceed to
nonmyeloablative allogeneic stem-cell transplantation (alloSCT) after HDM.
Maintenance was not given after alloSCT. Supportive care was given as de-
scribed in the Appendix (online only).
Table 1. Baseline Patient and Disease Characteristics
Characteristic
VAD
(n  414)
PAD
(n  413)
No. % No. %
Study group
HOVON 213 51 219 53
GMMG 201 49 194 47
Age, years
Median 57 57
Range 25-65 31-65
Male sex 247 60 253 61
WHO performance stage
0 183 44 193 47
1 173 42 170 41
2 47 11 31 8
3 8 2 15 4
Unknown 3 1 4 1
ISS stage
I 144 35 144 35
II 124 30 150 36
III 107 26 81 20
Unknown 39 9 38 9
M-protein isotype
IgA 97 23 92 22
IgG 234 57 251 61
IgD 3 1 5 1
LCD 78 19 63 15
Other 2 0 2 0
M-protein light chain
Kappa 278 67 277 67
Lambda 136 33 135 33
Unknown 0 0 1 0
Creatinine, mg/dL
 2 368 89 376 91
 2 45 11 36 9
Unknown 1 0 1 0
No. of skeletal lesions
0 96 23 102 25
1-2 42 10 44 11
 3 264 64 255 62
Unknown 12 3 12 3
Serum LDH
 ULN 331 80 329 80
 ULN 72 17 72 17
Unknown 11 3 12 3
Genetic abnormalities
del(13q)
Done 372 90 361 88
Positive, % of done 164 44 148 41
t(4;14)
Done 262 63 250 61
Positive, % of done 35 13 35 14
del(17p13)
Done 313 76 289 70
Positive, % of done 40 13 25 9
Median 2-microglobulin, mg/L 3.40 3.40
Median hemoglobin, mmol/L 6.7 6.6
Median calcium, mmol/L 2.31 2.34
Median No. of bone marrow plasma cells 45 40
Abbreviations: GMMG, German Multicenter Myeloma Group; HOVON,
Dutch-Belgian Hemato-Oncology Cooperative Group; Ig, immunoglobulin;
ISS, International Staging System; LCD, light-chain disease; LDH, serum
lactate dehydrogenase; PAD, bortezomib, doxorubicin, dexamethasone; ULN,
upper limit of normal; VAD, vincristine, doxorubicin, dexamethasone.
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Fig 1. CONSORT diagram of 827 adult patients with multiple myeloma (MM) in the Dutch-Belgian Hemato-Oncology Group 65/German Multicenter Myeloma Group
HD4 (HOVON-65/GMMG-HD4) study by treatment arm. allo-SCT, allogeneic stem-cell transplantation; CAD, cyclophosphamide, doxorubicin, dexamethasone; G-CSF,
granulocyte colony-stimulating factor; HDM, high-dose melphalan; PAD, bortezomib, doxorubicin, and dexamethasone; R, random assignment; RIC, reduced intensity
conditioning; VAD, vincristine, doxorubicin, and dexamethasone. (*) Including one patient with thalidomide plus bortezomib and one patient with thalidomide only. (†)
NFDY, no further data yet.
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Table 2. Response After Induction, After High-Dose Melphalan, and Overall, According to Prognostic Factors
Response
VAD (n  414) PAD (n  413)
PNo. % No. %
Response after induction
CR 7 2 29 7  .001
 nCR 20 5 46 11  .001
 VGPR 59 14 174 42  .001
 PR 222 54 322 78  .001
Response after HDM
CR 37 9 85 21  .001
 nCR 62 15 127 31  .001
 VGPR 150 36 254 62  .001
 PR 312 75 363 88  .001
Response overall
CR 99 24 147 36  .001
 nCR 140 34 201 49  .001
 VGPR 230 56 312 76  .001
 PR 343 83 373 90 .002
Response upgrade during maintenance
Any response upgrade 99 24 93 23 .64
 CR3CR 45 11 48 12 .73
 nCR3nCR 16 4 23 6 .25
 VGPR3VGPR 27 7 20 5 .30
 PR3PR 11 3 2 0 .008
ISS stage I (n  144) (n  144)
CR 37 26 59 41 .006
 nCR 58 40 78 54 .018
 VGPR 94 65 115 80 .005
 PR 130 90 132 92 .68
ISS stage II (n  124) (n  150)
CR 29 23 51 34 .05
 nCR 35 28 70 47 .002
 VGPR 59 48 109 73  .001
 PR 100 81 134 89 .04
ISS stage III (n  107) (n  81)
CR 24 22 26 32 .14
 nCR 35 33 35 43 .14
 VGPR 57 53 56 69 .03
 PR 82 77 70 86 .09
ISS stage unknown (n  39) (n  38)
CR 9 23 11 29 .56
 nCR 12 31 18 47 .13
 VGPR 20 51 32 84 .002
 PR 31 79 37 97 .01
2-microglobulin  3 mg/L (n  220) (n  223)
CR 50 23 77 35 .006
 nCR 67 30 103 46  .001
 VGPR 114 52 163 73  .001
 PR 173 79 198 89 .004
Creatinine  2 mg/dL (n  45) (n  36)
CR 6 13 13 36 .02
 nCR 12 27 19 53 .02
 VGPR 18 40 28 78  .001
 PR 29 64 31 86 .02
Genetic abnormalities
del(13/13q14) (n  164) (n  148)
 nCR 53 32 76 51  .001
 VGPR 88 54 124 84  .001
t(4;14) (n  35) (n  35)
 nCR 11 31 20 57 .03
 VGPR 20 57 30 86 .007
del(17p13) (n  40) (n  25)
 nCR 8 20 13 52 .008
 VGPR 17 43 18 72 .02
Abbreviations: CR, complete response; HDM, high-dose melphalan; ISS, International Staging System; nCR, near complete response; PAD, bortezomib,
doxorubicin, dexamethasone; PR, partial response; VAD, vincristine, doxorubicin, dexamethasone; VGPR, very good partial response.
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Thisstudywasapprovedbytheethicscommitteesof theErasmusUniversity
Medical Center, the University of Heidelberg, and the participating sites. All pa-
tientsgavewritten informedconsent, and the trialwasconductedaccording to the
EuropeanClinical TrialDirective 2005 and theDeclaration ofHelsinki.
Response Assessments and End Points
Clinical characteristics were recorded at diagnosis. Cytogenetic studies
were performed as described in the Appendix.29 Evaluation of response was
performed according to modified European Group for Blood and Marrow
Transplantation (EBMT) criteria.30 Near CR (nCR) and very good partial
response (VGPR) were implemented as in the InternationalMyelomaWork-
ing Group (IMWG) response criteria.31 nCR was defined as CR with positive
or missing immunofixation,8 and VGPR was defined as more than 90%
reductionof serumM-proteinandurine light chain less than100mg/24hours.
CR required negative serum/urine immunofixation and bone marrow mor-
phology evaluation. Responses were assessed after induction, after first and
second transplantation, at 2-month intervals during maintenance, and until
progression. PFS was calculated from random assignment until progression,
relapse, or death, whichever came first. Patients who received a nonmyeloab-
lative alloSCT, however, were censored at the date of alloSCT. PFS without
censoring of alloSCT patients has been denoted as PFSA. OS was measured
from randomassignment until death fromany cause. Patients alive at the date
of last contact were censored.
Statistical Analysis
The primary objective of the study was to compare PFS between the
treatment arms. The expected PFS in the VAD arm was 50% at 3 years. To
detect a hazard ratio (HR) of 0.74 with a power of 80%, which corresponds to
an increase of 3-year PFS from 50% to 60% (two-sided significance level of
  .049, because of one planned interim analysis at a significance level of
  .001), and assuming 3 years of accrual, additional follow-up time of 2
years, and 10% alloSCT, 800 patients had to be randomly assigned and 356
events had to be observed. All analyses were performed by intention-to-treat,
and the primary analysis was done with a multivariate Cox regression that
included adjustment for ISS stage.
Secondary end points included response, PFSA (without censoring pa-
tients with alloSCT), PFS/PFSA from last HDM, OS, safety, and toxicity. The
detailed statistical analysis is provided in the Appendix.
RESULTS
Patients
In all, 833 patients were recruited fromMay 2005 to May 2008.
Two (VAD) and four (PAD) ineligible patients were excluded from
analyses because theyhadnonsecretingmyeloma (n 4),misdiagno-
sis, or prior treatment (n  2). Thus, 827 patients were randomly
assigned to VAD (n 414) or PAD (n 413). Patient characteristics
at inclusion did not differ between the two groups (Table 1). Eighty-
one patients (10%) with impaired renal function (Durie -Salmon
stage B; serum creatinine more than 2mg/dL) were included.
Adherence to Treatment
The flow of patients through the protocol is shown in Figure 1.
Intensification with first HDM was achieved in 84% of patients, and
69%ofGMMGpatients completed a secondHDM.Of those patients
in the VAD arm, 77 (22%) of 347 went off protocol after HDM
because of alloSCT (n 21; 6%), persisting toxicity (n 11; 3%), or
other reasons (n  45; 13%), although 270 patients (78%) started
maintenance treatment. In the PAD arm, 123 (35%) of 352 patients
went off protocol because of alloSCT (n 28; 8%), persisting toxicity
(n 47; 13%, mainly polyneuropathy), or other (n 48; 14%), and
229 (65%) started maintenance with bortezomib (P  .004; Fig 1).
Persisting toxicitywasanexclusioncriteriumfor startingmaintenance
and, within the group of patients who went off protocol (excluding
alloSCTpatients), thiswasobserved in11 (14%)of 77 in theVADarm
versus 47 (38%) of 123 in the PAD arm (P .001). Normal comple-
tion ofmaintenance was achieved in 73 (27%) of 270 patients (VAD)
and 109 (47%) of 229 patients (PAD; Appendix Table A1, on-
line only).
Response
Overall response is given in Table 2. The CR rate was 24% in
patients who were randomly assigned to VAD and 36% in patients
randomlyassigned toPAD(P .001).OverallnCRplusCRrateswere
34% versus 49%, respectively (P  .001). After induction, all re-
sponses (ie, at least partial response [PR], at least VGPR, and at least
nCR) were superior in the PAD arm. Response rates increased from
induction to significantly higher than equal to or greater than VGPR
and equal to or greater than nCR following HDM/ASCT in the PAD
arm.The response rate fornCRplusCRafter transplantationwas15%
(VAD) versus 31% (PAD), respectively (P  .001). During mainte-
nance, an upgrade of response (from less than PR to PR, less than
VGPR to VGPR, less than nCR to nCR, or less than CR to CR) was
Table 3. Multivariate Analysis of Risk Factors for PFS and OS
Risk Factor
PFS OS
HR 95% CI P HR 95% CI P
PAD treatment arm 0.74 0.62 to 0.89 .001 0.77 0.60 to 1.00 .049
Age (years) 1.00 0.99 to 1.02 .53 1.00 0.99 to 1.02 .61
Female sex 0.85 0.70 to 1.02 .08 0.85 0.65 to 1.11 .24
ISS stage (I, II, III) 1.24 1.09 to 1.41 .001 1.45 1.21 to 1.74  .001
WHO PS (0, 1, 2, 3) 1.25 1.11 to 1.42  .001 1.52 1.29 to 1.79  .001
IgA 1.59 1.19 to 2.13 .002 1.81 1.19 to 2.75 .006
IgG† 1.33 1.03 to 1.72 .03 1.54 1.07 to 2.23 .02
Durie-Salmon stage 3 1.02 0.79 to 1.33 .86 1.02 0.70 to 1.48 .93
LDH  ULN 1.28 1.01 to 1.63 .04 1.68 1.24 to 2.29 .001
del(13/13q14) 1.39 1.13 to 1.70 .002 1.70 1.29 to 2.23  .001
SG (double HDM policy) 0.87 0.73 to 1.05 .15 0.75 0.57 to 0.97 .03
Abbreviations: HDM, high-dose melphalan; HR, hazard ratio; Ig, immunoglobulin; ISS, International Staging System; LDH, lactate dehydrogenase; OS, overall
survival; PAD, bortezomib, doxorubicin, dexamethasone; PFS, progression-free survival; PS, performance status; SG, study group; ULN, upper limit of normal.
M-protein is IgA compared with no IgA (IgG, IgD, light-chain disease, and other).
†M-protein is IgG compared with no IgG (IgA, IgD, light-chain disease, and other).
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observed in 24%of patients in theVADarmand23% in thePADarm
(Table 2). The median time to any response upgrade after start of
maintenance was 6months for VAD (range, 1 to 35months) versus 7
months for PAD (range, 1 to 57months).
PFS and OS
ThemedianPFSwas 28months for theVADarmand35months
for the PAD arm. Patients who were assigned to PAD had a signifi-
cantly better PFS (HR, 0.75; 95% CI, 0.62 to 0.90; P  .002) when
adjusted for ISS(primaryanalysis) andalso in themultivariateanalysis
(HR, 0.74; 95% CI, 0.62 to 0.89; P .001; Table 3, and Fig 2A). The
median PFSA (ie, without censoring of alloSCT) was 28 months
(VAD) versus 34months (PAD), respectively (Fig 2B).
Median OS was not reached at 66 months in either arm, with
5-year OS of 55% (VAD) versus 61% (PAD; Fig 2C). When OS was
adjusted for ISS, an HR of 0.81 (95% CI, 0.63 to 1.05; P .11) was
noted, but OS difference reached statistical significance in the multi-
variate analysis (HR, 0.77; 95%CI, 0.60 to1.00;P .049). It shouldbe
noted that both HRs and 95% CIs are quite similar. OS also differed
between study groups, with the GMMG patients having a better OS
(HR,0.75; 95%CI, 0.57 to0.97;P .03).Ananalysis ofPFScalculated
from the time of last HDM (n 645) showed a significant difference
in favor of the PAD arm, with a median of 26 months versus 31
months (AppendixFigA1A,onlineonly).This indicates that although
post-transplantation bortezomib and thalidomide both achieved re-
sponse upgrades, bortezomib contributedmore to improvement of PFS.
Ina landmarkanalysis startingat12monthsafter randomassignment for
585 patients (283, VAD; 302, PAD) who had receivedHDM/ASCT and
were still without progression, PFS (P .04; Appendix FigA1B) andOS
(P .05; Appendix FigA1C)were improved in the PADarm.
Safety
The safety profiles and most common toxicities are listed in
Appendix Table A2 (online only). Peripheral neuropathy (PNP) oc-
curredmore often in the PAD arm.Within the first year of treatment,
PNP grades 2 to 4 were reported in 18% (VAD) and 40% (PAD) of
patients (HR, 1.50; 95%CI, 1.20 to 1.88;P .001). In addition, newly
developed grade 3 to 4 PNP occurred in 8%of patients during thalid-
omide maintenance and 5% of patients during bortezomib
maintenance. In 82 (30%) of 270 patients receiving thalidomide
maintenance, toxicity was a reason to stop treatment prematurely
compared with 26 (11%) of 229 patients receiving bortezomibmain-
tenance (P  .001). The most frequent toxicities occurring during
maintenance are listed in Appendix Table A2. Progression or relapse
were reasons to stop maintenance prematurely in 86 (32%) of 270
patientsduring thalidomide treatmentversus74(32%)of229patients
during bortezomib treatment.
Secondary Analyses
To explore a possible differential effect of bortezomib treatment
in any of the subgroups, the effect of treatment was estimated sepa-
ratelybyHRs forPFSandOS,with associated95%CIs combinedwith
tests for interaction. The interactions were especially significant for
serum creatinine, fluorescent in situ hybridization (FISH) del(13q14)
and FISH del(17p13). Results of these subgroups are presented in
detail in Neben et al.32 Bortezomib resulted in a superior outcome in
patients with increased serum creatinine. In these patients, both me-
dian PFS (13 v 30 months; HR, 0.45; 95% CI, 0.26 to 0.78; P .004)
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Fig 2. Kaplan-Meier survival curves among patients with multiple myeloma,
according to randomly assigned treatment arm. (A) Progression-free survival
(censored at allogeneic stem-cell transplantation); (B) progression-free survival
(not censored at allogeneic stem-cell transplantation); (C) overall survival. adj. ISS,
adjusted for International Staging System stage; Cox LR, Cox logistic regression;
D, number of deaths; F, number of treatment failures (ie, progression, relapse, or
death); PAD, bortezomib, doxorubicin, and dexamethasone; VAD, vincristine,
doxorubicin, and dexamethasone.
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and OS (21 v 54 months; HR, 0.33; 95% CI, 0.16 to 0.65; P .001)
dramatically improvedwith bortezomib comparedwithVAD/thalid-
omide (Fig 3). Inpatientswithnormal serumcreatinine, PFS (median
31 v 35 months; HR, 0.80; 95% CI, 0.66 to 0.97; P .02) remained
superior in the PAD arm, but OS was similar between the arms (59%
v 62% at 5 years; HR, 0.94; 95%CI, 0.71 to 1.25; P .94).
Subgroup analyses were also performed for FISH abnormali-
ties, such as del(13q14), t(4;14), and del(17p13) (Table 1). In these
analyses, patients with abnormal FISH results were compared with
all patients without the abnormality. In patients with del(13q14), a
negative impact on PFS was observed in both treatment arms (Fig
4A). OS in patients with this deletion was similar to the OS in
patients with no del(13q14) in the PAD arm and significantly
better than OS in the VAD arm (median OS, 49 v 59 months; HR,
0.60; 95%CI, 0.42 to 0.87; P .007; Fig 4B). t(4;14) was associated
with worse PFS (HR, 1.76; 95% CI, 1.32 to 2.36; P .001) and OS
(HR, 2.13; 95%CI, 1.45 to 3.15;P .001). Although PADachieved
better results in patients with t(4;14), this did not reach statistical
significance (Figs 4C and 4D).
In patients with del(17p13), both PFS (median PFS, 12 v 22
months; HR, 0.47; 95% CI, 0.26 to 0.86; P  .01; Fig 4E) and OS
(median OS, 24 v 54 months; HR, 0.36; 95% CI, 0.18 to 0.74; P
.003; Fig 4F) were significantly better in the PAD arm. In patients
without del(17p13), OS was identical in both treatment arms (HR,
0.96; 95%CI, 0.69 to 1.34;P .81). An analysis of all FISHabnormal-
ities has been published separately.32
Because the doubleHDM/ASCTpolicy was statistically signif-
icant in the multivariate analysis for OS, it was decided to also
analyze some of the outcomes for HOVON (single HDM/ASCT)
and GMMG (double HDM/ASCT). In the HOVON patients, the
nCR/CR rate aftermaintenance was 29% in the VAD arm and 47%
in the PAD arm (odds ratio, 2.21; 95% CI, 1.49 to 3.30; P .001).
The median PFS was 24 months versus 32 months (HR, 0.70; 95%
CI, 0.55 to 0.91;P .006).OSwas 55%at 5 years in both arms (HR,
0.87; 95% CI, 0.62 to 1.20; P  .39). In the GMMG patients, the
nCR/CR rate aftermaintenance was 39% in the VAD arm and 51%
in the PAD arm (odds ratio, 1.58; 95% CI, 1.06 to 2.35; P  .03).
The median PFS was 31 months versus 36 months (HR, 0.80; 95%
CI, 0.62 to 1.04; P .09). OS was 54% versus 70% at 5 years (HR,
0.69; 95% CI, 0.46 to 1.04; P .07).
DISCUSSION
This randomized multicenter trial in patients with MM who were
eligible for high-dose therapy demonstrates that bortezomib during
induction and maintenance treatment results in a better response,
quality of response, PFS, andOS. In this trial, no random assignment
formaintenance therapywas performed; consequently, this cannot be
independently assessed. Instead, we attempted to determine whether
bortezomib before and after high-dose therapy might result in pro-
longed PFS. Maintenance treatment with bortezomib for 2 years was
A
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Fig 3. Kaplan-Meier survival curves of progression-free survival and overall survival according to treatment arm within subgroups according to creatinine level at
presentation. (A) Progression-free survival in patients with creatinine  2 mg/dL (VAD [vincristine, doxorubicin, and dexamethasone], gold; PAD [bortezomib,
doxorubicin, and dexamethasone], gray) or more than 2 mg/dL (VAD, blue; PAD, red). (B) Overall survival in patients with creatinine  2 mg/dL (VAD, gold; PAD, gray)
or more than 2 mg/dL (VAD, blue; PAD, red). D, number of deaths; F, number of treatment failures (ie, progression, relapse, or death).
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much better tolerated than thalidomide maintenance, with fewer pa-
tients stopping their treatment prematurely. Bortezomib mainte-
nance significantly improved the nCRplusCR rate from31% to 49%.
A landmark analysis indicated that nCR plus CR at 12 months was
associated with better PFS and OS. The subgroup analyses show that
the superior outcome with bortezomib is predominantly accom-
plished in patients with high-risk disease, myeloma-related renal fail-
ure, and del(17p). There seemed to be less difference in PFS between
the treatment arms inpatientswithout thehigh-risk characteristics. In
addition, OSwas better in the GMMGgroup, which performed stan-
dard double HDM with ASCT in 69% of patients in contrast to
HOVON(singleHDM).Previous trialshavenot clearlydemonstrated
a survival benefit of double versus single HDM.33,34 Because the trial
was not powered to compare single versus doubleHDM, the question
remains open.
Other studies have explored induction treatment with bortezomib
in two-or three-drug combinations suchasbortezomibanddexametha-
sone (BD), BD with cyclophosphamide (VCD), BD with thalidomide
(VTD), or BD with lenalidomide (VRD) in newly diagnosed pa-
tients. All observed a higher VGPR or CR rate and/or an improve-
ment of PFS but not OS compared with standard treatment.13,35-38 The
Intergroupe Francophone du Mye´lome (IFM 2005-01) trial35 was not
designed to evaluate OS. In the Gruppo Italiano Malattie Ematologiche
dell’Adulto (GIMEMA) and University of Arkansas for Medical
Sciences (UAMS) TT2 and TT3 trials, there was no difference in
OS.25,36 In Total Therapy 3, bortezomib was given from induction
through consolidation and maintenance, resulting in a 5-year OS
of 72%.39 Bortezomib consolidation after HDM was recently in-
vestigated.25 Monotherapy of 20 injections over 21 weeks was well
tolerated (mean total dose, 82%), the rate of VGPR or better
increased from 39% to 70%, and median PFS increased from 20
months (VAD) to 27 months (PAD).
The Spanish PETHEMA group used VTD induction without
consolidation, showing a post-ASCTCR rate of 46%.40 In GIMEMA,
VTDinductionandconsolidationafterHDMresulted inan improved
CR from 19% after induction to 42% after second HDM and 49%
after consolidation.13 These results indicate that post-HDM consoli-
dation with bortezomib may increase CR or VGPR. Maintenance
treatment with bortezomib, as in this trial, may offer the same CR/
nCR and an improved PFS and OS.
Bortezomib-emergent peripheral neuropathy (BiPN) was the
prevalent toxicity during induction, preventing a substantial num-
ber of patients from starting maintenance. In those who started
maintenance, 5% experienced BiPN grade 3 to 4 toxicity. More
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patients were unable to complete thalidomide maintenance treat-
ment. Hence, the lower percentage of failures in the bortezomib
arm may have contributed to the better PFS/OS in that group.
Prolonged administration of bortezomib in the once every 2 weeks
schedule seems feasible, and therefore it is important to prevent
BiPN during induction, enabling patients to continue into main-
tenance. The tolerability of the two-weekly schedule is in line with
the reported weekly schedule.4 In addition, subcutaneous admin-
istration may further improve tolerability.41 Recently, a significant
prolongation of PFS and/or OS was demonstrated with lenalido-
mide maintenance after high-dose therapy.23,24 Future trials will
address the optimal choice for maintenance treatment.
Oursubgroupanalyses revealed thatbortezomibwas superior for
CR/nCR, PFS, andOS in patients presenting with renal insufficiency,
almost to the level of patients without organ failure. Although the
safety and efficacy of bortezomib in renal failure has been observed in
phase II studies,42-44 this trial prospectively defines the benefit of
bortezomib in these high-risk patients.
The reported better outcomewith bortezomib of patients with t(4;
14)wasnotconfirmed.Althoughbortezomibtreatmentresultedinbetter
PFS and OS, the outcome remained inferior compared with patients
without t(4;14). Bortezomib significantly improved PFS and OS in pa-
tientswithdel(13q14) andmore importantly in del(17p13), identifying a
potential effective treatment option in this high-risk group. In the recent
IFM trial17 that used bortezomib plus dexamethasone for induction, no
improvement of PFS was observed in patients with del(17p), indicating
that induction with bortezomib may not be sufficient and that longer
treatmentmay be required for better outcome. Because a plateau in PFS
andOSwas not observed, longer follow-up is warranted. In conclusion,
bortezomibduring induction andmaintenance improves response, PFS,
andOS inpatientswithMM.
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CORRECTIONS
Author Correction
The June 10, 2012, article by Lynch et al, entitled, “Ipili-
mumab in Combination With Paclitaxel and Carboplatin As First-
Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer:
Results From a Randomized, Double-Blind, Multicenter Phase II
Study” (J Clin Oncol 30:2046-2054, 2012) contained an error.
In the Results section, under Efficacy, the last sentence of
the second paragraph was given as: “Rates of OS for phased
ipilimumab, concurrent ipilimumab, and control group were
42%, 50%, and 39%, respectively, at 1 year and 16%, 18%, and
18%, respectively, at 2 years.”
While it should have been: “Rates of OS for concurrent
ipilimumab, phased ipilimumab, and control group were
42%, 50%, and 39%, respectively, at 1 year and 16%, 18%, and
18%, respectively, at 2 years.”
The authors apologize for the mistake.
DOI: 10.1200/JCO.2012.46.6904; published May 20, 2012
■ ■ ■
Journal Correction
The August 20, 2012, article by Sonneveld et al, entitled,
“Bortezomib Induction and Maintenance Treatment in Pa-
tients With Newly Diagnosed Multiple Myeloma: Results of the
Randomized Phase III HOVON-65/GMMG-HD4 Trial”
(J Clin Oncol 30:2946-2955, 2012), contained errors.
In the Results section, under PFS and OS, the fifth sentence
of the second paragraph referenced Figure 3A, whereas it
should have been Appendix Figure A1A, as follows: “An analy-
sis of PFS calculated from the time of last HDM (n  645)
showed a significant difference in favor of the PAD arm, with a
median of 26 months versus 31 months (Appendix Fig A1A,
online only).”
Also under PFS and OS, in the last sentence of the second
paragraph, Figures 3B and C were referenced, whereas it should
have been Appendix Figures A1B and C, as follows: “In a
landmark analysis starting at 12 months after random assign-
ment for 585 patients (283, VAD; 302, PAD) who had received
HDM/ASCT and were still without progression, PFS (P .04;
Appendix Fig A1B) and OS (P .05; Appendix Fig A1C) were
improved in the PAD arm.”
In the Results section, under Secondary Analyses, the
second-to-last sentence of the first paragraph referenced Figure
4, whereas it should have been Figure 3, as follows: “In these
patients, both median PFS (13 v 30 months; HR, 0.45; 95% CI,
0.26 to 0.78; P .004) and OS (21 v 54 months; HR, 0.33; 95%
CI, 0.16 to 0.65; P  .001) dramatically improved with bort-
ezomib compared with VAD/thalidomide (Fig 3).”
Also under Secondary Analyses, in the second and third
paragraphs, Appendix Figures A1A-F were referenced, whereas
it should have been Figures 4A-F, as follows: “In patients with
del(13q14), a negative impact on PFS was observed in both
treatment arms (Fig 4A). OS in patients with this deletion was
similar to the OS in patients with no del(13q14) in the PAD arm
and significantly better than OS in the VAD arm (median OS,
49 v 59 months; HR, 0.60; 95% CI, 0.42 to 0.87; P  .007; Fig
4B). t(4;14) was associated with worse PFS (HR, 1.76; 95% CI,
1.32 to 2.36; P .001) and OS (HR, 2.13; 95% CI, 1.45 to 3.15;
P  .001). Although PAD achieved better results in patients
with t(4;14), this did not reach statistical significance (Figs 4C
and 4D). “In patients with del(17p13), both PFS (median PFS,
12 v 22 months; HR, 0.47; 95% CI, 0.26 to 0.86; P .01; Fig 4E)
and OS (median OS, 24 v 54 months; HR, 0.36; 95% CI, 0.18
to 0.74; P  .003; Fig 4F) were significantly better in the PAD
arm. In patients without del(17p13), OS was identical in both
treatment arms (HR, 0.96; 95% CI, 0.69 to 1.34; P .81).”
Journal of Clinical Oncology apologizes for the mistakes.
DOI: 10.1200/JCO.2012.46.6912; published May 20, 2012
■ ■ ■
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